FDA RESUME - Unknown Company

**FDA Document Summary: Scott Lim**

**Company Name:** Dohmen Life Science Services (DLSS), Emeryville, CA

**Inspection Dates:** Not specified in the document.

**Main Violations/Issues:** The document does not explicitly list specific violations or issues. However, it outlines the professional responsibilities of Scott Lim, focusing on maintaining compliance with Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), and Good Pharmacovigilance Practice (GVP) standards. It emphasizes the importance of conducting audits, managing quality systems, and ensuring adherence to regulatory requirements.

**Regulatory Framework:** The document highlights the regulatory framework involving GCP, GLP, GMP, and GVP, which are critical for ensuring the safety, quality, and efficacy of pharmaceutical products. It also mentions interactions with the FDA and other health agencies, indicating a comprehensive understanding of regulatory compliance.

**Required Actions:** While specific corrective actions are not detailed, the document suggests ongoing responsibilities such as: - Conducting internal and external audits to assess compliance. - Implementing and supporting compliance documentation and controls. - Preparing for inspection readiness and managing audit responses. - Developing corrective/preventive action plans and quality system improvements. - Providing consultation for quality system and gap analysis.

Overall, the document outlines Scott Lim's role in ensuring that DLSS maintains high standards of quality and compliance in its operations, with a focus on continuous improvement and adherence to regulatory guidelines.